Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tenaya Therapeutics Inc

0.6288
+0.01923.15%
Volume:602.18K
Turnover:381.50K
Market Cap:102.28M
PE:-0.55
High:0.6600
Open:0.6399
Low:0.6161
Close:0.6096
Loading ...

Tenaya Therapeutics publishes preclinical data on TN-201 in cardiac function

TipRanks
·
25 Mar

Promising Developments in Tenaya Therapeutics’ TN-201 Program Justify Buy Rating

TIPRANKS
·
25 Mar

Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial

MT Newswires Live
·
24 Mar

Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy

Simply Wall St.
·
24 Mar

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

GlobeNewswire
·
24 Mar

BRIEF-Tenaya Therapeutics files for mixed shelf offering of up to $300 mln

Reuters
·
22 Mar

Tenaya Therapeutics Inc: Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing

THOMSON REUTERS
·
22 Mar

Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
14 Mar

Promising Clinical Data and Financial Stability Support Buy Rating for Tenaya Therapeutics Despite Price Target Reduction

TIPRANKS
·
13 Mar

Tenaya Therapeutics price target lowered to $5 from $18 at H.C. Wainwright

TIPRANKS
·
11 Mar

Promising Clinical Developments and Strategic Advancements Support Buy Rating for Tenaya Therapeutics

TIPRANKS
·
11 Mar

Tenaya Therapeutics reports Q4 EPS (28c), consensus (31c)

TIPRANKS
·
11 Mar

BRIEF-Tenaya Therapeutics Q4 Net Income USD -23.836 Million Vs. IBES Estimate USD -27.1 Million

Reuters
·
11 Mar

Tenaya Therapeutics Q4 Operating Expenses USD 24.652 Million

THOMSON REUTERS
·
11 Mar

Tenaya Therapeutics Q4 Net Income USD -23.836 Million VS. Ibes Estimate USD -27.1 Million

THOMSON REUTERS
·
11 Mar

Tenaya Therapeutics Q4 Operating Income USD -24.652 Million VS. Ibes Estimate USD -28.2 Million

THOMSON REUTERS
·
11 Mar

Press Release: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Dow Jones
·
11 Mar

Insider Moves: Semtech, BioMarin, Yum!, Tenaya, Aurinia

TIPRANKS
·
08 Mar

Tenaya Therapeutics Announces Public Offering Pricing

TIPRANKS
·
05 Mar

Top Midday Decliners

MT Newswires Live
·
05 Mar